| Project/Area Number |
16K15510
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Collagenous pathology/Allergology
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Fujio Keishi 東京大学, 医学部附属病院, 教授 (70401114)
|
|---|
| Research Collaborator |
KOMAI TOSHIHIKO 東京大学, 医学部附属病院, 特任臨床医 (50803938)
INOUE MARIKO 東京大学, 医学部附属病院, 特任臨床医 (60816601)
MORITA KAORU 東京大学, 医学部附属病院, 特任臨床医
TERUYA SHUZO 東京大学, 医学部附属病院, 特任臨床医
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 制御性T細胞 / TGF-β / LAG3 / TGF-β3 / IL-10 / TGF-beta3 / Egr2 / サイトカイン / TGF-beta / ノックアウトマウス |
|---|
| Outline of Final Research Achievements |
The aim of this project was to elucidate the role of inhibitory cytokine in regulatory T cell (Treg)-mediated control of autoimmunity. Although inhibitory cytokines, such as transforming growth factor-β (TGF-β) and interleukin-10 (IL-10) play major roles in maintaining immune homeostasis, therapeutic application of inhibitory cytokines remains limited due to their pleiotropic and context-dependent effects. In this study, we reveled that a combination of TGF-β and IL-10, but not single cytokine, is required to suppress B cell activation induced by toll-like receptor (TLR) stimulation both in vitro and in vivo. The combination of these two inhibitory cytokines synergistically suppressed cellular energetics of both glycolysis and oxidative phosphorylation in B cells. By exploiting the cytokine synergy-mediated immune suppression, they may provide a new therapeutic method in autoantibody-mediated autoimmune diseases.
|
